IPA (ImmunoPrecise) IPA-TSXV covid - outsourced research vaccine co

Canadian Junior Gold and Silver - research report, mine visit report, discussion, comments, information for a specific company. Hui commentary by Dsquare.

Moderator: coach247

Post Reply
Posts: 1080
Joined: Thu May 22, 2008 1:42 pm

IPA (ImmunoPrecise) IPA-TSXV covid - outsourced research vaccine co

Post by SAPlayer » Wed Dec 30, 2020 8:49 pm

It's a novel concept to me mostly in smallcaps/tech space but lately with COVID19 obv you'd have to be blind to not spot the tnred in pharma and tech deals pivoting to COIVID related work.

At first I wrote off IPA.v as it shot up from $10 to over $25 post 5:1 rollback and listed promptly on NASDAQ, where markets are bigger and dollars are larger.
But I took a further look at the insiders, strong scientists and serious board, and I changed my mind a bit.

IPA’s CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television

VICTORIA, October 6, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, is scheduled to appear as a guest on BNN Television on Wednesday, Oct 7th, at approximately 11:30 am ET.

In light of recent events pertaining to President Trump’s SARS-CoV-2 infection, Dr. Bath will discuss current therapeutics in the clinic as well as IPA’s Polytope™ therapy and vaccine strategies. The Company believes it has launched the most comprehensive and diverse global antibody discovery program, which, unlike current approaches, is designed to provide durable, long-lasting treatment for the entire population and potential virus mutations.

About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise’s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact solutions@immuno

Insider ownership
Management / Jennifer Bath doesn't own a lot but these are all ex-Pharma major senior execs.
Lot of real R&D and sales BD team who I imagine are chasing Merck and GSK all day for contract outsource deals for scientists.
Lower overhead and higher chance of success, hard to argue

The Board, and previous promoters/smallcap brokers own enough they are insiders.
PAUL ANDREOLA who runs well known small cap digest (SCD) holds nearly 1.2 million shares (stocks at $20/share)
MIKO MALBERG another insider holds 800k shares and has been selling down lately at recent highs.

As mentioned before - this is a contract research business - from what I can understand they are the outsource research R&D firm for big pharma.
revenue has clearly picked up - not to mention tons of research grants and gov assistance due to COVID exposure and related R&D deals.
The spinoout parent co is NameSilo tech (URL:TSXV_ which still holds 3% of a now $400M company.

Company is cashed up and recent quarters were generating $3-4M revenue with $450-900K EBITDA range.


Uplist to NASDAQ was just Dec 30.
I thikn there's a good run way in 2021 - obv not quite a penny stock but worth a look for those who wants some biotech smallcap exposure
Post Reply